New Delhi: Sun Pharmaceutical Industries reported a consolidated net profit of Rs 982.51 crore for the June quarter of 2018-19.
The company had posted a net loss of Rs 424.92 crore in the year-ago quarter on account of an exceptional item, Sun Pharmaceutical said in a filing to BSE.
Total revenue from operations stood at Rs 7,224.17 crore for the reported quarter. It was Rs 6,208.79 crore in the same period a year ago. “For the first quarter, we have recorded good growth in all the major markets,” Sun Pharmaceutical Industries MD Dilip Shanghvi said.
The company is gradually crossing key milestones in its specialty initiatives with the recent commercialization of Yonsa in the US and targeted launch of Ilumya and Cequa in the coming quarters, he added.
“We are also awaiting approvals from USFDA for two specialty products — Xelpros and Elepsia — filed from Halol,” Shanghvi said.
The company is creating a deep pipeline of specialty products. However, during the year these launches will result in significant upfront investments, he added. “We continue to evaluate opportunities in the specialty segment to further enhance this business,” Shanghvi said.
Sale of branded formulations in India for June quarter 2018 was Rs 2,152 crore, up 22 percent from the same period of 2017-18 and accounted for 30 percent of total sales, Sun Pharma said.
Sales in the US were USD 380 million (around Rs 2,654 crore) for the quarter under review, a growth of 8 percent over same period last year and accounted for 36 percent of total sales, Sun Pharma said.
Emerging Markets sales contributed USD 195 million (over Rs 1,360 crore) for the first quarter of 2018-19, a growth of 16 percent year-on-year and accounted for 18 percent of total sales, it added.
Formulation sales in Rest of World (RoW) markets excluding the US and Emerging Markets were USD 107 million (around Rs 747 crore) in the reported quarter, a decline of 7 percent from the year-ago period and accounted for around 10 percent of revenues, Sun Pharma said.
External sales of the active pharmaceutical ingredients (APIs) for the June quarter were at Rs 394 crore, up 28 percent from the same period a year ago.
The company received the Establishment Inspection Report (EIR) from USFDA for the Halol facility in June 2018, it said.